Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 Est; Affirms FY2026 Sales Guidance of $270.00
Ligand Pharmaceuticals (NASDAQ: LGND ) raises FY2026 Adj EPS guidance from $8.50-$9.50 to $9.00-$9.50 vs $9.16 analyst estimate. Affirms FY2026 sales outlook from $270.000 million-$310.000 million to $270.000 million-$310.000 million vs $288.559 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.